The treatment resulted in improved skin texture and it made my skin appear more clear
UV light, for instance, carries enough energy to break chemical bonds, a process known as photodegradation
Abbreviations ACPs: Anticancer peptides PDCs: Peptidedrug conjugates HNP-1: Human neutrophil peptide LfcinB: Lactoferrin GHRH: Growth hormone-releasing hormone STAT3: Signal transducer and activator of transcription 3 GSH: Glutathione ADCs: Antibodydrug conjugates mAb: Monoclonal antibody USFDA: US Food and Drug Administration BBB: Bloodbrain barrier SORT1: Sortilin 1 DTX: Docetaxel NSCLC: Non-small cell lung cancer HDM-2: Human double minute 2 Apaf-1: Apoptotic protease-activating factor-1 ROS: Reactive oxygen species TP53: Tumor protein 53 AIF: Apoptosis-inducing factor EndoG: Endonuclease G PLP2: Proteolipid protein 2 DAMPs: Damage-associated molecular patterns HMGB1: High-mobility group protein B1 VEGF: Vascular endothelial growth factor PDGF: Platelet-derived growth factor FGF: Fibroblast growth factor CK2: Casein kinase 2 MMP: Matrix metalloproteinase VEGF-A: Vascular endothelial growth factor ALA-A2: Alpha-lactalbumin-A2 IC50: Half maximal inhibitory concentration DCs: Dendritic cells Treg: Regulatory T cell IFN-: Interferon-gamma HLA: Human leukocyte antigen IL-2: Interleukin-2 PEG: Polyethylene glycol MOMP: Mitochondrial outer membrane permeabilization Cyt c: Cytochrome c AIF: Apoptotic-inducing factor mPTP: Mitochondrial permeability transition pore IMM: Inner mitochondria membrane VDAC: Voltage-dependent anion channels MTD: Mitochondrial-targeting domain UCPVax: Universal cancer peptide-based vaccine RhoC: Ras homolog gene family member C SSRT2: Somatostatin receptor-2 References Abdelmageed MI, Abdelmoneim AH, Mustafa MI, Elfadol NM, Murshed NS, Shantier SW, Makhawi AM (2020) Design of a multiepitope-based peptide vaccine against the E protein of human COVID-19: an immunoinformatics approach
Objective response, according to mRECIST criteria, was observed in 2/14 (14.3%) and 6/18 (33.3%) patients of group A1 and A2, respectively
The STEP 1 trial demonstrated a mean body weight reduction of 14.9% at the 2.4mg maintenance dose over 68 weeks, compared to just 2.4% in the placebo group
Adhering to these practices helps preserve sample quality and supports reliable experimental outcomes
